Author

H. Tani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 9 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 8 Organism:human· 4 Organism:mouse· 3 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Y. Saga· 5 shared M. Saijo· 4 shared S. Fukushi· 4 shared S. Taniguchi· 4 shared T. Shimada· 4 shared Y. Morinaga· 4 shared E. Yamazaki· 3 shared K. Oishi· 3 shared

Activity by Year

2018-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

Y. Saga

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus

M. Kimura, R. Matsuoka, S. Taniguchi, J. Maruyama, S. Paessler, S. Oka, A. Yamashita, T. Fukuhara, Y. Matsuura, H. Tani

This study identifies CB1 receptor antagonists as inhibitors of Lujo virus entry by suppressing viral membrane fusion and reducing infectivity in vitro.

bioRxiv · May 24, 2023Microbiology

Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein

K. Waki, H. Tani, E. Kawahara, Y. Saga, T. Shimada, E. Yamazaki, S. Koike, Y. Morinaga, M. Isobe, N. Kurosawa

This study shows that multimeric secretory IgA from nasal mucosa provides effective protection against SARS-CoV-2, even when monomeric IgA is non-neutralizing.

bioRxiv · Apr 10, 2023Immunology

Neutralizing antibody levels and epidemiological information of patients with breakthrough COVID-19 infection in Toyama, Japan

H. Tani, N. Inasaki, T. Shimada, Y. Saga, H. Kaya, Y. Maruyama, S. Matano, H. Itoh, T. Kashii, E. Yamazaki, S. Yazawa, M. Itamochi, K. Oishi

This study examines neutralizing antibody levels and epidemiological data of patients with breakthrough COVID-19 infections in Toyama, Japan, finding that Omicron BA.1 variants show minimal neutralization despite prior vaccination.

bioRxiv · Feb 27, 2023Microbiology

Evaluation of SARS-CoV-2 isolation in cell culture from nasal/nasopharyngeal swabs or saliva specimens of patients with COVID-19

S. Yazawa, E. Yamazaki, Y. Saga, M. Itamochi, N. Inasaki, T. Shimada, K. Oishi, H. Tani

This study evaluates SARS-CoV-2 isolation efficiency from nasal/nasopharyngeal swabs and saliva, finding lower efficiency in saliva due to inhibitory factors like lactoferrin and amylase.

bioRxiv · Feb 16, 2023 · PreprintMicrobiology

Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19

E. Igarashi, T. Shimada, S. Yazawa, Y. Saga, M. Itamochi, N. Inasaki, Y. Morinaga, K. Oishi, H. Tani

This study examines how trypsin-like proteases affect SARS-CoV-2 infectivity in clinical specimens, finding significant increases for the delta variant compared to omicron.

bioRxiv · Sep 27, 2022 · PreprintMicrobiology

A novel hamster model of SARS-CoV-2 respiratory infection using a pseudotyped virus

H. Yamada, S. Sasaki, H. Tani, M. Somekawa, H. Kawasuji, Y. Saga, Y. Yoshida, Y. Yamamoto, Y. Hayakawa, Y. Morinaga

This paper develops a hamster model of SARS-CoV-2 infection using a pseudotyped virus, showing dose-dependent luminescence in the lungs.

bioRxiv · Sep 17, 2021Microbiology

Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein

H. Tani, L. Tan, M. Kimura, Y. Yoshida, H. Yamada, S. Fukushi, M. Saijo, H. Kawasuji, A. Ueno, Y. Miyajima, Y. Fukui, I. Sakamaki, Y. Yamamoto, Y. Morinaga

This study evaluates SARS-CoV-2 neutralizing antibodies using a pseudotyped virus assay and compares results with immunofluorescence assay findings.

bioRxiv · Aug 21, 2020Microbiology

A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome

T. Yoshikawa, S. Taniguchi, H. Kato, N. Iwata-Yoshikawa, H. Tani, T. Kurosu, H. Fujii, N. Omura, M. Shibamura, S. Watanabe, K. Egawa, T. Inagaki, S. Sugimoto, S. Phanthanawiboon, S. Harada, , M. Saijo

This paper develops and tests recombinant vaccinia virus vaccines against SFTS, showing they induce protective immunity and are safe in mice.

bioRxiv · Aug 6, 2020Microbiology

Characterization of the untranslated region of lymphocytic choriomeningitis virus S segment

S. Taniguchi, T. Yoshikawa, M. Shimojima, S. Fukushi, T. Kurosu, H. Tani, A. Fukuma, F. Kato, E. Nakayama, T. Maeki, S. Tajima, C.-K. Lim, H. Ebihara, S. Kyuwa, S. Morikawa, M. Saijo

This study investigates the functional roles of untranslated regions (UTRs) in the LCMV S segment, revealing their involvement in viral replication, transcription, and virulence, with implications for vaccine development.

bioRxiv · May 31, 2019 · PreprintMicrobiology

Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration

H. TANI, T. Komeno, A. Fukuma, S. Fukushi, S. Taniguchi, M. Shimojima, A. Uda, S. Morikawa, N. Nakajima, Y. Furuta, M. Saijo

This study shows that oral favipiravir at 120 or 200 mg/kg/day effectively treats SFTSV infection in IFNAR-/- mice when started within 4 days post-infection, preventing mortality.

bioRxiv · Aug 24, 2018Microbiology